Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CPA1 | P15085 | 2/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | CPA3 | P15088 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2317601 | 1.00 | KMT2A (0.49) | KMT2ASLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL6824207 | 1.00 | KMT2A (0.49) | KMT2ASLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL34471031 | 0.91 | TSHR (0.45) | KMT2ASLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL2312535 | 0.87 | ALDH1A1 (0.52) | KMT2ASLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL21536617 | 0.87 | ALDH1A1 (0.52) | KMT2ASLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL18112934 | 0.86 | SLC1A3 (0.44) | KMT2ASLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL20581847 | 0.86 | ALDH1A1 (0.50) | KMT2ASLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL7507596 | 0.86 | ALDH1A1 (0.50) | KMT2ASLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL29259157 | 0.85 | HTT (0.44) | ALDH1A1CPA1CPB1CPA3CPB2 | |
| SCHEMBL24335280 | 0.84 | MMP1 (0.48) | KMT2ASLC1A3SLC1A2SLC1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112521286-B | Preparation method and application of compound 3-hydroxy-3 ', 4' -dihydroxy-butyric acid phenethyl ester | 西安交通大学 | 2021-12-28 | — | — | CN | claimed |
| CN-112521286-A | Preparation method and application of compound 3-hydroxy-3 ', 4' -dihydroxy-butyric acid phenethyl ester | 西安交通大学 | 2021-03-19 | — | — | CN | claimed |
| US-20210078932-A1 | 3,4-DIHYDROXYPHENETHYL 3-HYDROXYBUTANOATE, PREPARATION AND USE THEREOF | CHENGDU MEDICAL COLLEGE (CN) | 2021-03-18 | — | — | US | claimed |
| WO-2026090272-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASE | 2508 BIOSCIENCES LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20240376059-A1 | Compounds for the Treatment of Alzheimer's Disease | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2024-11-14 | — | — | US | disclosed |
| EP-3634430-B1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-11939302-B2 | Compounds for the treatment of Alzheimer's disease | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2024-03-26 | — | — | US | disclosed |
| CN-117177744-A | CDK2 inhibitors and methods of use thereof | 塞迪拉治疗股份有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| CN-109071467-A | Acyclic antiviral agent | 艾丽奥斯生物制药有限公司 | 2018-12-21 | — | — | CN | disclosed |
| WO-2018226732-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
| WO-2017156262-A1 | ACYCLIC ANTIVIRALS | ALIOS BIOPHARMA, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| CN-102177137-B | 1-phenylpyrrole compounds | EXELIXIS INC | 2015-03-18 | — | — | CN | disclosed |
| WO-2012164473-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-12-06 | — | — | WO | disclosed |
| CN-102177137-A | 1-phenylpyrrole compounds | EXELIXIS INC | 2011-09-07 | — | — | CN | disclosed |
| US-6306828-B1 | ENTERIC OR PARENTAL SOLUTION OF ALPHA-AND/OR BETA-D-GLUCOPYRANOSYL C2-C20 ALKANOATE; WOUND HEALING AGENTS; DIETETICS; TRAUMAS, METABOLIC DISORDERS | BAXTER INTERNATIONAL, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-0736256-B1 | Enantiomerically-enhanced nutritional energy substrates | BAXTER INT (US) | 1999-06-23 | — | — | EP | disclosed |
| EP-0736256-A1 | Enantiomerically-enhanced nutritional energy substrates | CLINTEC NUTRITION COMPANY (US) | 1996-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | KMT2A 3546/4885SLC1A3 2178/4885SLC1A2 1783/4885 |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | KMT2A 3546/4885SLC1A3 2178/4885SLC1A2 1783/4885 |
| US-20240376059-A1 | Compounds for the Treatment of Alzheimer's Disease | IAPP, GPR119, APP | KMT2A 4597/4885SLC1A3 1063/4885SLC1A2 570/4885 |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | KMT2A 1842/4885SLC1A3 2515/4885SLC1A2 3039/4885 |
| US-20210078932-A1 | 3,4-DIHYDROXYPHENETHYL 3-HYDROXYBUTANOATE, PREPARATION AND USE THEREOF | HTR3B, HSD3B1, HTR3C | KMT2A 1097/4885SLC1A3 214/4885SLC1A2 371/4885 |
| US-11939302-B2 | Compounds for the treatment of Alzheimer's disease | IAPP, GPR119, APP | KMT2A 4597/4885SLC1A3 1063/4885SLC1A2 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.